Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab

CD4 + T Cell Help Confers a Cytotoxic T Cell Effector Program Including Coinhibitory Receptor Downregulation and Increased Tissue Invasiveness

(2017) Tomasz Ahrends et al.   IMMUNITY

Targeting Immune Checkpoints in Cancer Therapy

(2017) Suzanne L. Topalian   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Differential Inhibitory Receptor Expression on T Cells Delineates Functional Capacities in Chronic Viral Infection

(2017) Jeffrey E. Teigler et al.   JOURNAL OF VIROLOGY

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

(2017) Alexander C. Huang et al.   NATURE

Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer

(2017) Julienne L. Carstens et al.   Nature Communications

Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma

(2017) Axel Lechner et al.   Oncotarget

Merkel cell carcinoma

(2017) Jürgen C. Becker et al.   Nature Reviews Disease Primers

Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma

(2017) Elizabeth L. Yanik et al.   JAMA Oncology

Abstract 853: Novel quantitative multiplexed PD-1/PD-L1 immunohistochemistry test provides superior prediction of treatment response in melanoma patients

(2016) Jennifer Bordeaux et al.   CANCER RESEARCH

Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma

(2016) Laurence Feldmeyer et al.   CLINICAL CANCER RESEARCH

A morphological and immunophenotypic map of the immune response in Merkel cell carcinoma

(2016) Noreen M. Walsh et al.   HUMAN PATHOLOGY

Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

(2016) David F. McDermott et al.   JOURNAL OF CLINICAL ONCOLOGY

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

(2016) Howard L Kaufman et al.   LANCET ONCOLOGY

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

(2016) Paul T. Nghiem et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1hi Identifies a Novel Regulatory B-cell Population in Human Hepatoma That Promotes Disease Progression

(2016) X. Xiao et al.   Cancer Discovery

Classical Hodgkin Lymphoma with Reduced  2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status

(2016) M. G. M. Roemer et al.   Cancer Immunology Research

Reversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinoma

(2016) Cathrin Ritter et al.   Scientific Reports

PD-1/PD-L1 inhibitors

(2015) Joel Sunshine et al.   CURRENT OPINION IN PHARMACOLOGY

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer

(2015) J. R. Webb et al.   Cancer Immunology Research

CD8+ Lymphocyte Intratumoral Infiltration as a Stage-Independent Predictor of Merkel Cell Carcinoma Survival

(2014) Kelly G. Paulson et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

PD-L1 Expression in Melanocytic Lesions Does Not Correlate with the BRAF V600E Mutation

(2014) N. Rodi  et al.   Cancer Immunology Research

Tumor-Specific T Cells in Human Merkel Cell Carcinomas: A Possible Role for Tregs and T-Cell Exhaustion in Reducing T-Cell Responses

(2013) Mitra Dowlatshahi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Enhancement of Tumor-Reactive Cytotoxic CD4+ T-cell Responses after Ipilimumab Treatment in Four Advanced Melanoma Patients

(2013) S. Kitano et al.   Cancer Immunology Research

PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival

(2013) E. J. Lipson et al.   Cancer Immunology Research

PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer

(2012) C. Badoual et al.   CANCER RESEARCH

Tumor Infiltrating Immune Cells and Outcome of Merkel Cell Carcinoma: A Population-Based Study

(2012) H. Sihto et al.   CLINICAL CANCER RESEARCH

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

(2009) M. Ahmadzadeh et al.   BLOOD

Association of Merkel Cell Polyomavirus–Specific Antibodies With Merkel Cell Carcinoma

(2009) Joseph J. Carter et al.   JNCI-Journal of the National Cancer Institute

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER